TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19083412
Drug: Iron-fortified fermented
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified fermented milk beverage supplemented with Lactobacillus acidophilus (3 mg iron per 80 mL)
Study: 12939317
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate (0.6 mol/L)
Study: 7747212
Drug: Low social
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low social class, age 45-64 years, poor social network, not feeling secure in daily life, not taking regular exercise
Study: 3746
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D preparation
Study: 28363704
Drug: Interviewer-administered version
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interviewer-administered version of PM-3D4D
Study: 28363704
Drug: Self-administered version
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered version of PM-3D4D
Study: 23691266
Drug: Melatonin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (10 mg oral, 1 month before surgery)
Study: 16983909
Drug: Integrated Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Chinese and Western medicine (ICWM) protocol
Study: 16983909
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine plus placebo
Study: 15545307
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg R411 as a single oral dose
Study: 15545307
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg RO0270608 as an intravenous infusion
Study: 15545307
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of R411 (10-1200 mg)
Study: 15545307
Drug: Repeated oral
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated oral doses of R411 (50-900 mg) for up to 3 weeks
Study: 8289475
Drug: ETI (Etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETI (Etoposide 80 mg/m2, Thioguanine 100 mg/m2 twice a day on days 1-5, Idarubicin 15 mg/m2 on days 1-3)
Study: 8289475
Drug: TAD (Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAD (Oral Thioguanine 100 mg/m2 twice a day on days 1-5, i.v. Cytarabine, Daunorubicin 60 mg/m2 on day 5)
Study: 3301058
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of streptokinase
Study: 3301058
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment in the coronary care unit
Study: 24897083
Drug: Oritavancin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oritavancin (1200 mg single intravenous dose)
Study: 24897083
Drug: Vancomycin (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (twice daily for 7 to 10 days)
Study: 18349181
Drug: Oral ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ondansetron disintegrating tablets (ODT)
Study: 11320369
Drug: Eprosartan (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (400 to 800 mg daily)
Study: 10322821
Drug: Kangaibao oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangaibao oral liquid (KABOL)
Study: 8494577
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 20 mg
Study: 8494577
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 40 mg
Study: 8494577
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 80 mg
Study: 8494577
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 120 mg
Study: 8494577
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 180 mg
Study: 8494577
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 240 mg
Study: 8494577
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride 360 mg
Study: 3115081
Drug: Oligosaccharides infusion
Normalized name: chitosan oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligosaccharides infusion (144 +/- 41.0 g/day)
Study: 3115081
Drug: Oligosaccharides infusion
Normalized name: chitosan oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligosaccharides infusion
Study: 27846922
Drug: Brexpiprazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole (2 mg, 4 mg) in short-term fixed-dose studies
Study: 27846922
Drug: Brexpiprazole (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole (2-4 mg) in flexible-dose short-term study
Study: 27846922
Drug: Brexpiprazole in
Normalized name: Product containing brexpiprazole in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole in maintenance study (1-4 mg)
Study: 25829142
Drug: Raloxifene (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (120 mg daily)
Study: 20005355
Drug: Everolimus-based immunosuppression
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus-based immunosuppression regimen with discontinuation of cyclosporine or tacrolimus (group 2)
Study: 9153737
Drug: N-9 vaginal
Normalized name: (+/-)-N-methylephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-9 vaginal gel (Advantage-24), 52.5 mg, applied once daily for 2 weeks
Study: 9153737
Drug: Placebo gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel, applied once daily for 2 weeks
Study: 8423760
Drug: Prophylactic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prophylactic ibuprofen (400 mg TID initiated 4 h before exercise)
Study: 8423760
Drug: Therapeutic ibuprofen
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic ibuprofen (400 mg TID initiated 24 h after baseline)
Study: 15567009
Drug: Prophylactic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prophylactic ibuprofen
Study: 8423760
Drug: Prophylactic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic and therapeutic ibuprofen
Study: 31595954
Drug: Low-dose computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose computed tomography (LDCT) with prior AAD
Study: 22329591
Drug: Amlodipine 2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 2.5-5 mg plus amiloride/hydrochlorothiazide 1.25-2.5 mg/12.5-25 mg (Group A)
Study: 22329591
Drug: Amlodipine 2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 2.5-5 mg plus telmisartan 40-80 mg (Group T)
Study: 18457470
Drug: Agomelatine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 50 mg
Study: 18457470
Drug: Agomelatine 25
Normalized name: Agomelatine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 25 mg
Study: 12196749
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream dosed twice daily
Study: 12196749
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream dosed once daily
Study: 12196749
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream dosed 5 times a week
Study: 12196749
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream dosed 3 times a week
Study: 7760888
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 mg per day for 48 hours)
Study: 2328197
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg 12 hourly
Study: 2328197
Drug: Lomefloxacin 400
Normalized name: lomefloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin 400 mg 12 hourly
Study: 85937
Drug: Tienilic acid
Normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tienilic acid 250 mg/day combined with propranolol 80 mg twice daily
Study: 23657005
Drug: Transglucosidase (TGD)
Normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transglucosidase (TGD) 300 or 900 mg/day for 12 weeks
Study: 21851461
Drug: Serotonergic antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonergic antidepressant
Study: 17239888
Drug: Atorvastatin/Niacin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin/Niacin ER
Study: 2546778
Drug: Chemotherapy (etoposide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (etoposide, doxorubicin, methotrexate (VAM) and procarbacine, vincristine, cyclophosphamide, lomustine (POCC) with prophylactic cranial irradiation (30 Gy))
Study: 2546778
Drug: Sequential hemibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential hemibody irradiation (SHBI)
Study: 612628
Drug: Tinidazole, 50
Normalized name: Tinidazole, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole, 50 mg/kg once
Study: 612628
Drug: Metronidazole, 50
Normalized name: MetroNIDAZOLE, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole, 50 mg/kg once
Study: 31747959
Drug: abPI‐VSD (antibiotic-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: abPI‐VSD (antibiotic-containing drainage fluid)
Study: 31747959
Drug: Antibiotic irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic irrigation solution without abPI‐VSD
Study: 20597110
Drug: Abatacept 10
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept 10 mg/kg plus methotrexate (MTX) during the 4-month open-label period (period A)
Study: 17600622
Drug: Modafinil treatment
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil treatment for 2 weeks
Study: 17600622
Drug: Pre-treatment scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment scan
Study: 15764868
Drug: Propranolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (mean achieved dose 106 +/- 38 mg/d)
Study: 10606310
Drug: Golytely 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golytely 20 ml/kg (up to 1 L) per hour for 4 h with clear liquid diet for 1 day (group C)
Study: 8606813
Drug: Digoxin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.5 mg/daily)
Study: 2006519
Drug: Ciprofloxacin, 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, 750 mg p.o. b.i.d.
Study: 7152771
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg/kg body weight)
Study: 18095196
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate infusion (5 mg/kg bolus and 500 mg/h for 24 hours)
Study: 10655909
Drug: Nafamostat mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat mesilate (kallikrein inhibitor)
Study: 10655909
Drug: Lipid solvent
Normalized name: solvent yellow 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid solvent (injected twice)
Study: 1874199
Drug: Midazolam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.3 mg kg‐1 (Group 1)
Study: 1874199
Drug: Midazolam 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.6 mg kg‐1 (Group 2)
Study: 2319047
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg methylphenidate
Study: 6191948
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg/kg methylphenidate)
Study: 22806681
Drug: telaprevir treatment
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: telaprevir treatment
Study: 17323793
Drug: Deximune soft‐gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deximune soft‐gelatin capsules (200 mg CsA)
Study: 17323793
Drug: Sandimmune Neoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmune Neoral (200 mg CsA)
Study: 17323793
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (Deximune and Sandimmune)
Study: 11597376
Drug: Topical GM-CSF
Normalized name: axatilimab-csfr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical GM-CSF mouthwashes
Study: 11597376
Drug: Combined topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical use of antiseptic agent (povidone-iodine) and amphotericin B (AA)
Study: 1743806
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Parlodel-SRO administered in two intakes (b.i.d.)
Study: 1743806
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Parlodel-SRO administered in one dose (once daily)
Study: 1743806
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Parlodel-SRO administered in three intakes (t.i.d.)
Study: 31027422
Drug: Memantine extended
Normalized name: memantine extended release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine extended release treatment in MEM‐MD‐91 trial
Study: 31027422
Drug: Memantine extended
Normalized name: memantine extended release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine extended release treatment in MEM‐MD‐68 trial
Study: 31027422
Drug: Memantine extended
Normalized name: memantine extended release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine extended release treatment in MEM‐MD‐69 trial
Study: 27618090
Drug: 50 g-oats
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g-oats group (n = 80)
Study: 27618090
Drug: 100 g-oats
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g-oats group (n = 79)
Study: 23328283
Drug: Lactulose plus
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose plus live combined Bacillus subtilis and Enterococcus faecium capsules for 14 days, followed by only Bacillus subtilis and Enterococcus faecium capsules for 14 days
Study: 18060813
Drug: Pregabalin therapy
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin therapy
Study: 25172950
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 nmol l(‐1))
Study: 21358707
Drug: Citalopram (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (selective serotonin-uptake inhibitor) administered for 7 days
Study: 10319076
Drug: Aggressive diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive diet and exercise recommendations, lipid-lowering drugs according to NCEP guidelines
Study: 8732324
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (nitrendipine combined with enalapril and/or hydrochlorothiazide)
Study: 8517385
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg, titrated to a maximum of 40 mg/day
Study: 8517385
Drug: Pravastatin 10
Normalized name: pravastatin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10 mg, titrated to a maximum of 40 mg/day
Study: 3127574
Drug: Natural surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural surfactant preparation consisting of lipids extracted from calf lung lavage
Study: 26860807
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CHM) as maintenance therapy
Study: 25130788
Drug: Endothelial cell-selective
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelial cell-selective adhesion molecule levels in AKI group
Study: 16428753
Drug: ACAM2010 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACAM2010 vaccine (5 x 10^9 CFU)
Study: 11582899
Drug: Interpretive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpretive therapy
Study: 10446037
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of alpha-tocopherol (n = 27)
Study: 8005274
Drug: Episodic progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Episodic progesterone (P) administration (12.5 mg IM on days 2 and 7) during the artificial follicular phase (Group A)
Study: 8005274
Drug: Episodic progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Episodic progesterone (P) administration (6.25 mg on days 3, 4, and 5) during the artificial follicular phase (Group B)
Study: 4568265
Drug: Steroids for
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids for 7 to 8 days
Study: 24382580
Drug: Robotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic therapy (ARMin exoskeleton robot)
Study: 23477205
Drug: Dairy products
Normalized name: Food - Dairy Products, Whey, Cow's Milk
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy products (932 mg Ca; n = 19)
Study: 23477205
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate tablets (1000 mg calcium/day; n = 18)
Study: 18070045
Drug: Oxycodone controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone controlled release (Oxy-CR), 5-10 mg, q12 h/day
Study: 14657879
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3.7 g n‐3 PUFAs per day)
Study: 350263
Drug: Topical atenolol
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical atenolol (2% 3 times a day)
Study: 350263
Drug: Topical pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pilocarpine (2% 3 times a day)
Study: 350263
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2% pilocarpine and 2% atenolol administered 15 minutes apart (3 times a day)
Study: 26512597
Drug: PET-CT scan
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET-CT scan at 9 months (PET-CT9) after the start of radiation treatment
Study: 19242343
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 40,000 IU once weekly, subcutaneously (group A)
Study: 19242343
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa 40,000 IU once weekly, intravenously (group B)
Study: 19242343
Drug: All dosing
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dosing regimens of epoetin alfa
Study: 15679127
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg of tetracaine
Study: 15679127
Drug: 6.0 mg
Normalized name: Dimethicone 6.0 mg in 30 mL TOPICAL CREAM [Clapiel Revital Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.0 mg of tetracaine
Study: 9615801
Drug: MTH‐68/B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTH‐68/B vaccine treatment
Study: 8087786
Drug: Conformal three-dimensional
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conformal three-dimensional (3D) radiation treatment
Study: 8087786
Drug: Conventional radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional radiation treatment
Study: 2575369
Drug: Cicletanine 100
Normalized name: cicletanine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 100 mg/day
Study: 2514676
Drug: Cicletanine 200
Normalized name: cicletanine
DrugBank: Cicletanine (DB12766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cicletanine 200 mg/day
Study: 26510526
Drug: Astym therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astym therapy
Study: 26510526
Drug: Placebo (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham Astym treatment)
Study: 10102601
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine ointment
Study: 7788259
Drug: Intravesical methylene
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical methylene blue staining (1% solution)
Study: 7198462
Drug: Plafibride at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plafibride at 800 mg/d
Study: 7198462
Drug: Plafibride at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plafibride at 1600 mg/d
Study: 25867447
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (nicotine patch, nicotine lozenge, bupropion SR, patch and lozenge, or bupropion SR and lozenge)
Study: 25867447
Drug: Patch and
Normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch and lozenge combination
Study: 24028629
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces boulardii supplementation (250 mg/day)